
Hansoo Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4172420/publications.pdf Version: 2024-02-01



HANSOO KIM

#	Article	IF	CITATIONS
1	A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia. Value in Health, 2016, 19, 1009-1015.	0.3	24
2	Health Technology Assessment Challenges in Oncology: 20 Years of Value in Health. Value in Health, 2019, 22, 593-600.	0.3	21
3	Costâ€effectiveness and financial risks associated with immune checkpoint inhibitor therapy. British Journal of Clinical Pharmacology, 2020, 86, 1703-1710.	2.4	19
4	A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanoma. Journal of Pharmaceutical Policy and Practice, 2018, 11, 4.	2.4	13
5	Health Technology Assessment in Australia: The Pharmaceutical Benefits Advisory Committee and Medical Services Advisory Committee. Value in Health Regional Issues, 2021, 24, 6-11.	1.2	6
6	Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis. PharmacoEconomics - Open, 2021, 5, 459-467.	1.8	5
7	Reassessing the cost-effectiveness of nivolumab for the treatment of renal cell carcinoma based on mature survival data, updated safety and lower comparator price. Journal of Medical Economics, 2021, 24, 893-899.	2.1	2
8	The Potential for Early Health Economic Modelling in Health Technology Assessment and Reimbursement DecisionMaking Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling". International Journal of Health Policy and Management, 2021, 10, 98-101.	0.9	1
9	Current Issues in Health Technology Assessment of Cancer Therapies: A Survey of Stakeholders and Opinion Leaders in Australia. International Journal of Technology Assessment in Health Care, 2022, 38,	0.5	0